NCT03685591 · OUTCOME

Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors · Source last updated 2024-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Baseline up to 28 days after last dose of study treatment ( up to approximately 2 years)

What was measured

Laboratory parameters included: hematology (hemoglobin, hematocrit, red blood cell, platelet and white blood cell count, neutrophils, eosinophils, monocytes, basophils and lymphocytes), chemistry (blood urea nitrogen, creatinine, sodium, potassium, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein and serum pregnancy test \[for all female participants\]) and urine (urine pregnancy test \[for all female participants\]). Clinical significance of laboratory parameters was determined at the investigator's discretion.

Analysis population: Population included all enrolled participants who received at least one dose of investigational product and with at least one observation of the given laboratory test during treatment period. Here, "number analyzed" signifies participant evaluable for each row.

Groups in this outcome

Part 1A: PF-06952229 20mg Monotherapy

PF-06952229 was administered at a dose of 20 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days).

Part 1A: PF-06952229 40mg Monotherapy

PF-06952229 was administered at a dose of 40 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).

Part 1A: PF-06952229 80mg Monotherapy

PF-06952229 was administered at a dose of 80 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).

Part 1A: PF-06952229 150mg Monotherapy

PF-06952229 was administered at a dose of 150 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).

Part 1A: PF-06952229 250mg Monotherapy

PF-06952229 was administered at a dose of 250 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).

Part 1A: PF-06952229 375mg Monotherapy

PF-06952229 was administered at a dose of 375 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).

Part 1A: PF-06952229 500mg Monotherapy

PF-06952229 was administered at a dose of 500 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).

Part 1B: PF-06952229 250mg + Enzalutamide

PF-06952229 was administered at a dose of 250 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally once a day (QD) as continuous daily dosing.

Part 1B: PF-06952229 375mg + Enzalutamide

PF-06952229 was administered at a dose of 375 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally QD as continuous daily dosing.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.